Animal Models in Diabetes Mellitus: An Overview
Diabetes mellitus is defined as a state in which homeostasis of carbohydrate and lipid metabolism is improperly regulated by insulin. This results primarily in elevated fasting and postprandial blood glucose levels. If this imbalanced homeostasis dose not returns to normalcy and continues for a protracted period of time, it leads to hyperglycemia, which in due course turns into a syndrome called diabetes mellitus. Several animal models have been developed for studying diabetes mellitus or testing anti-diabetic agents. These models include chemical, surgical (pancreatectomy) and genetic manipulations in several animal species to induce diabetes mellitus. The diabetogenic drugs used include: Alloxan monohydrate, Streptozotocin with or without nicotinamide, Ferric nitrilotriacetate, Ditizona and Anti-insulin serum. The selection of these models to use for investigating the antidiabetic properties of a new compound may be a very difficult task especially for young researchers. The aim of the present review is give a brief idea about various experimental models developed for studying diabetes mellitus, assess the merits and demerits of each model and highlight the precautions needed to avoid erroneous results during the applications of these models.
Keywords: Diabetes Mellitus, Animal models, Alloxan, Streptozotocin.
2. Varughese GI, Scarpello JH. Treating dyslipidaemia in the setting of diabetes mellitus and cardiovascular disease: a less commonly perceived therapeutic perspective in clinical practice. Int J Clin Pract. 2006; 60(7):884-8.
3. World Health Organization & International Diabetes Federation. (2006). Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. Geneva: World Health Organization. http://www.who.int/iris/handle/10665/43588.
4. Catchpole B, Kennedy LJ, Davison LJ, Ollier WE. Canine diabetes mellitus: from phenotype to genotype. J Small Anim Pract. 2008; 49(1):4-10.
5. Buchanan TA, Xiang AH. Gestational diabetes mellitus. J Clin Invest. 2005; 115(3):485-91.
6. Baily CC, Baily OT .Production of diabetes mellitus in rabbits with alloxan: a preliminary report.J Am Med Ass 1943; 122:1165-6.
7. Dunn JS, McLetchie NGB, Experimental alloxan diabetes in the rat.Lancet 1943; 11:384-7.
8. Lenzen S,Panten U.Alloxan :History and mechanism of action .Diabetologia 1988; 31:337-42.
9. Kodoma, et al.A diabetes model induced by neonatal alloxan treatment in rats.Diab Res Clin Pract1993; 20:183-9
10. Rakieten, et al.Studies on the diabetogenic action of Streptozotocin (NSC 37917). Cancer chemotherapy Rep 1963; 29:91-8.
11. Povoski, et al.Induction of diabetes mellitus in Syrian golden hamster using stored equilibrium solutions of Streptozotocin .Lab Anim Sci 1993; 43:310-14.
12. Ar Rajab A, et al.Long term diabetogenic effect of Streptozotocin in rats .Pancreas 1993; 8:50-7.
13. Wright JR, et al.Synergistic effects of adjuvants,endotoxin and fasting on induction of diabetes with multiple low doses of Streptozotocin in rats. Diabetes 1988; 37:112-8.
14. Chattopadhya, et al.Animal models in experimental diabetes mellitus. Indian J Exp Biol 1997; 35:1142-5.
15. Ogawa A, et al. Roles of insulin resistance and β cell dysfunction in dexamethasone induced diabetes.J Clin Invest 1992; 90:497-503.
16. Hayhurst GP, et al. Hepatocyte Nuclear Factor 4alpha (Nuclear Receptor 2A1) is Essential for Maintenance of Hepatic Gene Expression and Lipid Homeostasis. Mol Cell Biol. 2001; 21:1393-1403.
17. Chaturvedi N, et al. circulating and urinary transforming growth factor-? 1, Amadori albumin, and complications of type 1 diabetes: the EURODIAB prospective complications study. Diabetes Care 2002; 25:2320-2327.
18. Al-Snafi AE. Therapeutic properties of medicinal plants: a review of plants with antidiabetic effects (part 1). J of Pharmaceutical Biology 2015; 5(3):218-229.
19. Agrawal SS, et al. Studies on Immunomodulatory Activity of Capparis zeylanica Leaf Extracts. Int J PharmaSci Nano. 2010, 3(1):887-892.
20. Verma S, et al. Immunomodulatory activity of Withania somnifera (L.). J Chem Pharm Res 2012, 4(1):559-561.
21. Leiter EH. NOD mice and related strains: origins, husbandry, and biology. In: Heiter EH, Atkinson MA (Eds). NOD mice and related strains: Research Applications in Diabetes, AIDS, Cancer, and other Diseases, Austin: RG Landes, 1998:1-15.
22. Chappel CI, Chappel WR. The discovery and the development of the BB rat colony; and animal model of spontaneous diabetes mellitus. Metabolism: Clinical and Experimental 1983; 32:8-10.
23. Blondel O, Bailbe D, Portha B. Relation of insulin deficiency to impaired insulin action in NIDDM adult rats given streptozotocin as neonates. Diabetes 1989; 38:610-17.
24. Weir GC, et al. Islet secretion in a new experimental model for noninsulindependent diabetes. Diabetes 1981; 30:590-95.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).